S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
NASDAQ:IOVA

Iovance Biotherapeutics (IOVA) Stock Forecast, Price & News

$8.80
+0.07 (+0.80%)
(As of 06/2/2023 ET)
Compare
Today's Range
$8.66
$9.00
50-Day Range
$5.36
$9.06
52-Week Range
$5.28
$13.44
Volume
4.96 million shs
Average Volume
4.52 million shs
Market Capitalization
$1.98 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.09

Iovance Biotherapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
116.9% Upside
$19.09 Price Target
Short Interest
Bearish
12.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.53
Upright™ Environmental Score
News Sentiment
0.42mentions of Iovance Biotherapeutics in the last 14 days
Based on 26 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.39) to ($1.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

296th out of 983 stocks

Biological Products, Except Diagnostic Industry

42nd out of 164 stocks


IOVA stock logo

About Iovance Biotherapeutics (NASDAQ:IOVA) Stock

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

IOVA Stock News Headlines

Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Admin
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
What's Going On With Iovance Biotherapeutics Stock?
Where Iovance Biotherapeutics Stands With Analysts
JMP Securities Remains a Buy on Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics (IOVA) Gets a Hold from Goldman Sachs
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 6%
See More Headlines

IOVA Price History

IOVA Company Calendar

Last Earnings
5/09/2023
Today
6/02/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IOVA
Fax
N/A
Employees
319
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$19.09
High Stock Price Forecast
$38.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+116.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

Net Income
$-395,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.97 per share

Miscellaneous

Free Float
201,106,000
Market Cap
$1.98 billion
Optionable
Optionable
Beta
0.18

Social Links


Key Executives

  • Frederick G. Vogt
    President, CEO, Secretary & General Counsel
  • Igor P. Bilinsky
    Chief Operating Officer
  • Jean-Marc Bellemin
    CFO & Principal Accounting Officer
  • Friedrich Graf Finckenstein
    Chief Medical Officer
  • Brian Shew
    SVP & Head-Information Technology













IOVA Stock - Frequently Asked Questions

Should I buy or sell Iovance Biotherapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IOVA shares.
View IOVA analyst ratings
or view top-rated stocks.

What is Iovance Biotherapeutics' stock price forecast for 2023?

11 analysts have issued 12 month price targets for Iovance Biotherapeutics' stock. Their IOVA share price forecasts range from $6.00 to $38.00. On average, they predict the company's stock price to reach $19.09 in the next year. This suggests a possible upside of 116.9% from the stock's current price.
View analysts price targets for IOVA
or view top-rated stocks among Wall Street analysts.

How have IOVA shares performed in 2023?

Iovance Biotherapeutics' stock was trading at $6.39 at the start of the year. Since then, IOVA shares have increased by 37.7% and is now trading at $8.80.
View the best growth stocks for 2023 here
.

When is Iovance Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our IOVA earnings forecast
.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) issued its quarterly earnings data on Tuesday, May, 9th. The biotechnology company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.84) by $0.34. During the same quarter last year, the business posted ($0.58) EPS.

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (6.83%), State Street Corp (6.12%), BlackRock Inc. (5.55%), Price T Rowe Associates Inc. MD (1.67%), Boxer Capital LLC (1.65%) and Artisan Partners Limited Partnership (1.59%). Insiders that own company stock include Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum.
View institutional ownership trends
.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $8.80.

How much money does Iovance Biotherapeutics make?

Iovance Biotherapeutics (NASDAQ:IOVA) has a market capitalization of $1.98 billion. The biotechnology company earns $-395,890,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis.

How many employees does Iovance Biotherapeutics have?

The company employs 319 workers across the globe.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The official website for the company is www.iovance.com. The biotechnology company can be reached via phone at (650) 260-7120 or via email at achang@troutgroup.com.

This page (NASDAQ:IOVA) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -